LAG3 and neoplasm: Similarly, CRISPR/Cas9 mediated the deletion of lymphocyte activation gene-3 (LAG-3) (a negative regulator of T-cell activity) was found to improve the anti-tumor effect of CAR-T cells in the murine xenograft model [159].